At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
Nesiritide +1 moredrug
Likely dose
Nesiritide 2 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.
In Brief
A Phase 4 clinical trial evaluating Nesiritide and Nitroglycerin for Acute Decompensated Heart Failure. Completed, enrolled 89 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Decompensated Heart Failure
CountriesUnited States
CollaboratorsAmerican College of Clinical Pharmacy
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
Primary CompletionJul 2008
Study CompletionFeb 2009
First PostedFeb 2009
TodayJul 2026
First PostedFeb 12, 2009
Enrollment StartJul 1, 2006
Primary CompletionJul 1, 2008
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.4 years ago
Interventions
Nesiritidedrug
Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
Nitroglycerindrug
5-10 mcg/min titrating per protocol based on blood pressure